Skip to main content

Recent developments in therapeutic cancer vaccines.

Publication ,  Journal Article
Morse, MA; Chui, S; Hobeika, A; Lyerly, HK; Clay, T
Published in: Nat Clin Pract Oncol
February 2005

Therapeutic cancer vaccines are being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Clin Pract Oncol

DOI

ISSN

1743-4254

Publication Date

February 2005

Volume

2

Issue

2

Start / End Page

108 / 113

Location

England

Related Subject Headings

  • Research Design
  • Oncology & Carcinogenesis
  • Neoplasms
  • Immunotherapy
  • Humans
  • Endpoint Determination
  • Dendritic Cells
  • Combined Modality Therapy
  • Clinical Trials as Topic
  • Cancer Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Chui, S., Hobeika, A., Lyerly, H. K., & Clay, T. (2005). Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol, 2(2), 108–113. https://doi.org/10.1038/ncponc0098
Morse, Michael A., Stephen Chui, Amy Hobeika, H Kim Lyerly, and Timothy Clay. “Recent developments in therapeutic cancer vaccines.Nat Clin Pract Oncol 2, no. 2 (February 2005): 108–13. https://doi.org/10.1038/ncponc0098.
Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol. 2005 Feb;2(2):108–13.
Morse, Michael A., et al. “Recent developments in therapeutic cancer vaccines.Nat Clin Pract Oncol, vol. 2, no. 2, Feb. 2005, pp. 108–13. Pubmed, doi:10.1038/ncponc0098.
Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol. 2005 Feb;2(2):108–113.

Published In

Nat Clin Pract Oncol

DOI

ISSN

1743-4254

Publication Date

February 2005

Volume

2

Issue

2

Start / End Page

108 / 113

Location

England

Related Subject Headings

  • Research Design
  • Oncology & Carcinogenesis
  • Neoplasms
  • Immunotherapy
  • Humans
  • Endpoint Determination
  • Dendritic Cells
  • Combined Modality Therapy
  • Clinical Trials as Topic
  • Cancer Vaccines